Neumora Therapeutics (NASDAQ:NMRA) President Sells $21,123.18 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Joshua Pinto sold 5,967 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $3.54, for a total transaction of $21,123.18. Following the sale, the president directly owned 57,783 shares of the company’s stock, valued at approximately $204,551.82. This represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Neumora Therapeutics Trading Down 2.6%

Shares of Neumora Therapeutics stock opened at $3.39 on Friday. Neumora Therapeutics, Inc. has a 1-year low of $0.61 and a 1-year high of $3.65. The company’s fifty day simple moving average is $2.20 and its 200-day simple moving average is $2.08. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. The stock has a market capitalization of $566.43 million, a PE ratio of -2.31 and a beta of 3.20.

Trending Headlines about Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: William Blair upgraded NMRA from Market Perform to Outperform, a catalyst that helped lift shares and drew investor attention. Neumora Therapeutics (NASDAQ:NMRA) Stock Rating Upgraded by William Blair
• Positive Sentiment: Other broker research has become more bullish in recent months (Needham, RBC, Mizuho), with several firms raising price targets — a supportive backdrop for shares and longer‑term sentiment. MarketBeat: Neumora Therapeutics coverage and analyst notes
• Neutral Sentiment: Institutional ownership is meaningful (~47.7%); a mix of hedge funds/institutions recently took or adjusted positions, which can amplify moves but doesn’t signal a directional near‑term catalyst by itself. MarketBeat: Hedge funds and institutional ownership
• Neutral Sentiment: Company profile: Neumora is a clinical‑stage CNS biotech with an R&D pipeline across small molecules, biologics and gene modalities — typical risk/reward profile for a clinical-stage drug developer. MarketBeat: About Neumora Therapeutics
• Negative Sentiment: Multiple insiders sold shares on Feb. 17 (President Joshua Pinto: 5,967 shares; Paul L. Berns: 9,819; Daljit Singh Aurora: 6,165; Michael Lee Milligan: 1,436) — roughly ~23k shares disclosed — which can create downward pressure and signal near‑term caution to investors. Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) President Sells 5,967 Shares of Stock

Analyst Ratings Changes

NMRA has been the subject of several recent research reports. Guggenheim raised Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. Mizuho set a $6.00 target price on shares of Neumora Therapeutics in a research note on Monday, January 5th. Leerink Partners initiated coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They set an “outperform” rating and a $8.00 price target on the stock. Finally, Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $4.00 to $7.00 in a report on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Neumora Therapeutics has an average rating of “Hold” and a consensus price target of $8.13.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NMRA. Invesco Ltd. increased its holdings in Neumora Therapeutics by 23.8% in the 4th quarter. Invesco Ltd. now owns 227,594 shares of the company’s stock valued at $407,000 after acquiring an additional 43,795 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Neumora Therapeutics during the 4th quarter valued at about $204,000. Ikarian Capital LLC grew its position in shares of Neumora Therapeutics by 10,128.9% during the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after purchasing an additional 1,265,910 shares in the last quarter. Susquehanna Portfolio Strategies LLC grew its position in shares of Neumora Therapeutics by 74.8% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 72,106 shares of the company’s stock valued at $129,000 after purchasing an additional 30,866 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Neumora Therapeutics by 80.1% in the fourth quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after purchasing an additional 1,608,266 shares during the last quarter. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.